Article

Lakshmanan Krishnamurti Named Chief of Pediatric Hematology, Oncology, and Bone Marrow Transplant at Yale New Haven Children’s Hospital and Smilow Cancer Hospital

Author(s):

Lakshmanan Krishnamurti, MD, has been named Chief of Pediatric Hematology, Oncology, and Bone Marrow Transplant at Yale New Haven Children’s Hospital and Leader of the Smilow Cancer Hospital Pediatric Hematology/Oncology Program.

Lakshmanan Krishnamurti, MD

Lakshmanan Krishnamurti, MD

Lakshmanan Krishnamurti, MD, has been named Chief of Pediatric Hematology, Oncology, and Bone Marrow Transplant at Yale New Haven Children’s Hospitaland Leader of the Smilow Cancer Hospital Pediatric Hematology/Oncology Program. Krishnamurti is an accomplished pediatric hematologist oncologist and an international leader in bone marrow transplant and the treatment of hemoglobinopathies.

“We’re very excited to welcome Dr. Krishnamurti to these critical leadership positions. His expertise will propel our pediatric hematology, oncology, and bone marrow transplant teams ,” said Nita Ahuja, MD, MBA, FACS, Interim Director of Yale Cancer Center and Physician-in-Chief at Smilow Cancer Hospital, William H. Carmalt Professor of Surgery, and Chair of Surgery. “I am confident Dr. Krishnamurti’s expertise will continue to expand the impact of our clinical and research advances for our pediatric patients with cancer and their families.”

“I look forward to Dr. Krishnamurti bringing his expertise to help strengthen our clinical programs, expand our basic science, translational and clinical research efforts, grow the section’s educational programs, and expand faculty development and mentoring efforts,” said Clifford Bogue, MD, Waldemar Von Zedtwitz Professor and Chairman of Pediatrics at Yale School of Medicine and Chief Medical Officer at Yale New Haven Children’s Hospital. "We're excited for him to join us in making Yale New Haven Children’s Hospital and Yale Pediatrics a top destination for care.”

Krishnamurti joins Yale from Emory University School of Medicine where he is Director of the Bone Marrow Transplantation Program and Professor of Pediatrics and holds the Joseph Kuechenmeister Aflac Field Force Chair at Children’s Healthcare of Atlanta. He received his MBBS from University of Poona, Armed Forces Medical College, India and completed a pediatrics residency at University of Bombay, India. Krishnamurti attended University of Minnesota for his pediatric residency and fellowship in pediatric hematology, oncology, and bone marrow transplant.

Krishnamurti starts in his new position October 1, 2021.

About Yale Cancer Center and Smilow Cancer Hospital

Yale Cancer Center (YCC) is one of only 51 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.

About Yale New Haven Children’s Hospital

Yale New Haven Children’s Hospital (YNHCH) offers Connecticut’s largest and most comprehensive array of pediatric services. With 212 licensed beds, YNHCH includes two neonatal intensive care units, a pediatric cardiac intensive care unit, a pediatric intensive care unit, a 24-hour pediatric emergency room and a pediatric surgery center. YNHCH, with campuses in New Haven and Bridgeport, is part of the nationally recognized Yale New Haven Hospital, a 1,541-bed not-for-profit teaching hospital affiliated with Yale School of Medicine. The Yale New Haven Hospital campuses and associated ambulatory sites are Magnet-designated by the American Nurses Credentialing Center. In addition to its inpatient units, YNHCH has three Pediatric Specialty Centers in New Haven and others in Norwalk, Greenwich, Trumbull and Old Saybrook to provide specialty care to children closer to their communities.

Related Videos
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
David Rimm, MD, PhD
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
David Rimm, MD, PhD
A panel of 3 experts on nasopharyngeal carcinoma
David Rimm, MD, PhD
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma